Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial

Table 1 Baseline characteristics of study patients n (%)

	PEG-IFNα with entecavir (n = 21)	PEG-IFNα alone (n = 19)	P value
Age (mean, yr)	26.4 ± 6.4	27 ± 7.4	0.946
Gender (male:female)	16:5	15:4	1.00
Body mass index (kg/m2)	21.8 ± 3.6	23.6 ± 4.3	0.151
Hemoglobin (g/dL)	13.7 ± 1.59	13.9 ± 1.3	0.473
Total leucocyte count (× 106/L)	7.1 ± 2.0	6.7 ± 1.9	0.626
Platelets count (× 109/L)	237 ± 83	185 ± 59	0.0231
Total bilirubin (mg/dL)	0.67 ± 0.34	0.70 ± 0.38	0.828
ALT (IU/L)	87 ± 55	89 ± 41	0.379
GGT (IU/L)	49 ± 41	69 ± 72	0.255
Inflammatory grade on biopsy			0.186
0-1	5 (31)	1 (5)
2-3	16 (69)	18 (95)
Fibrosis stage on biopsy			0.105
0-2	12 (57)	6 (32)
3-4	9 (43)	13 (68)
Cirrhosis	2 (10)	6 (32)	0.120
HBeAg reactive	7 (33)	7 (37)	0.816
HDV RNA (mean log10 IU/mL)	7.5 ± 1.1	6.9 ± 1.2	0.119
HBV DNA detected	5 (24)	5 (26)	1.00
HBV DNA (mean log10 IU/mL)	1.08 ± 2.10	1.48 ± 2.70	0.656
HBsAg (mean log10 IU/mL)	4.50 ± 0.42	4.20 ± 0.64	0.068

¹Significant P value. ALT: Alanine aminotransferase; GGT: Gamma glutamyl transferase; HBeAg: Hepatitis B e antigen; HDV: Hepatitis D virus; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; PEG-IFNα: Pegylated interferon alfa.